<div id="readability-page-1"><div><ul> <li>If you are trying to work out whether Celcuity's current share price makes sense, this article walks through how its value stacks up using several common yardsticks.</li> <li>The stock last closed at US$117.10, with recent returns of 9.0% over 7 days, 9.7% over 30 days, 16.5% year to date, and very large gains over 1 year and 3 years.</li> <li>Recent news around Celcuity has focused on its position in the pharmaceuticals and biotech space and how investors are reacting to its progress on key programs and partnerships. This context helps explain why sentiment has shifted so sharply and why the market is paying close attention to future milestones.</li> <li>Simply Wall St's valuation checks give Celcuity a 2 out of 6 score for being undervalued. Next we will look at what different valuation approaches say about the stock and then finish with a way to go beyond the usual valuation tools.</li> </ul> <p>Celcuity scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.</p> <h3>Approach 1: Celcuity Discounted Cash Flow (DCF) Analysis</h3> <p>A Discounted Cash Flow, or DCF, model takes estimates of the cash a business could generate in the future and discounts those amounts back to today to arrive at an estimate of what the company might be worth now.</p> <p>For Celcuity, Simply Wall St uses a 2 Stage Free Cash Flow to Equity model based on projected free cash flows in $. The latest twelve month free cash flow is a loss of $144.9 million. Analyst estimates and subsequent extrapolations point to free cash flow of $766.9 million by 2030, with a path that includes both negative and positive projected cash flows over the next decade.</p> <p>Discounting these projected cash flows back to today produces an estimated intrinsic value of about $548.56 per share. Compared with the recent share price of US$117.10, this model suggests a discount of 78.7%, which indicates the shares screen as heavily undervalued on this DCF view.</p> <p><strong>Result: UNDERVALUED</strong></p> <p>Our Discounted Cash Flow (DCF) analysis suggests Celcuity is undervalued by 78.7%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f1973a75-d572-4daf-9945-4916c94ccd9e/chart/dcf/query-ZGF0ZT0yMDI2LTAzLTEx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f1973a75-d572-4daf-9945-4916c94ccd9e/chart/dcf/query-ZGF0ZT0yMDI2LTAzLTEx"/><figcaption>CELC Discounted Cash Flow as at Mar 2026</figcaption></figure> <p>Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Celcuity.</p> <h3>Approach 2: Celcuity Price vs Book</h3> <p>For companies that are not yet profitable, earnings based metrics such as the P/E ratio are less useful, so investors often look at asset based measures like the Price to Book, or P/B, ratio instead. Book value reflects the net assets on the balance sheet, which can provide a reference point when earnings are still developing.</p> <p>In general, higher expected growth and lower risk tend to justify a higher “normal” valuation multiple, while more uncertainty or weaker profitability usually lead investors to prefer a lower multiple. With P/B, you are effectively asking how many dollars you are paying for each dollar of net assets, adjusted in your own mind for those growth and risk factors.</p> <p>Celcuity currently trades on a P/B of 46.33x, compared with an average of 2.71x for the Biotechs industry and about 13.19x for its peer group. Simply Wall St’s proprietary “Fair Ratio” takes this a step further by estimating what P/B might be reasonable after considering the company’s earnings growth profile, industry, profit margins, market cap and risk characteristics. Because it is tailored to Celcuity rather than broad groups, it can give a more targeted view than simple comparisons to industry or peers. With the Fair Ratio not provided here, you can use these benchmarks as context rather than a firm verdict.</p> <p><strong>Result: ABOUT RIGHT</strong></p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f1973a75-d572-4daf-9945-4916c94ccd9e/chart/pb-multiple-vs-industry/query-ZGF0ZT0yMDI2LTAzLTEx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f1973a75-d572-4daf-9945-4916c94ccd9e/chart/pb-multiple-vs-industry/query-ZGF0ZT0yMDI2LTAzLTEx"/><figcaption>NasdaqCM:CELC P/B Ratio as at Mar 2026</figcaption></figure> <p>P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.</p> <h3>Upgrade Your Decision Making: Choose your Celcuity Narrative</h3> <p>Earlier we mentioned that there is an even better way to understand valuation. Let us introduce you to Narratives, a simple tool on Simply Wall St’s Community page. With Narratives, you lay out your own story for Celcuity, link that story to specific forecasts for revenue, earnings and margins, and arrive at a fair value you can compare directly with the current share price. This can help you decide whether you see it as an opportunity or as fully priced. That fair value automatically updates as new information such as trial data, regulatory news or earnings arrives. For example, one investor might build a bullish Celcuity Narrative around the higher earnings expectation of US$351.8 million and a US$155.0 fair value. Another might anchor to the US$127.2 million earnings case and a US$94.0 fair value. This neatly captures their different views in numbers rather than just opinions.</p> <p>Do you think there's more to the story for Celcuity? Head over to our Community to see what others are saying!</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f1973a75-d572-4daf-9945-4916c94ccd9e/chart/quote-price/query-ZGF0ZT0yMDI2LTAzLTEx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f1973a75-d572-4daf-9945-4916c94ccd9e/chart/quote-price/query-ZGF0ZT0yMDI2LTAzLTEx"/><figcaption>NasdaqCM:CELC 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><div><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies</p><p>Or build your own from over 50 metrics.</p></div><p>Explore Now for Free</p></div></div></div>

<p>Celcuity's current share price of US$117.10 is analyzed through various valuation methods, revealing it is undervalued by 78.7% based on a Discounted Cash Flow (DCF) analysis, which estimates an intrinsic value of about $548.56 per share. The company has a Price to Book (P/B) ratio of 46.33x, significantly higher than industry averages, indicating a fair valuation. Investors are encouraged to use the Narratives tool to assess their own valuation perspectives based on future earnings forecasts and market developments.</p>

Simplywall

VG Health

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

Health Care Select Sector SPDR

SPDR S&P Biotech

ALPS Medical Breakthrough

Celcuity

VanEck Biotech ETF

iShares Biotechnology ETF

Is Celcuity (CELC) Pricing Reflecting Its Sharp Rally And DCF-Heavy Discount?